Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418727 · ClinicalTrials.gov registry record · Phase 2
Dry Eye Disease Study With Brimonidine
A Phase 2 study, sponsored by Ocugen.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT03418727: Completed Phase 2 study, sponsored by Ocugen.
NCT03418727 is a Phase 2 study that has completed, run by Ocugen. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03418727, a Phase 2 study, has completed, sponsored by Ocugen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
Primary Outcome
Participants assessed their tolerance to the administration of the study drug, utilizing a VAS. The VAS is a 100-mm horizontal line with verbal descriptors at either end. Participants placed a single slash mark across the horizontal line between the end labeled "completely intolerable" (0 mm) and "easily tolerable" (100mm).
Interventions
- DRUG Brimonidine
- DRUG Brimonidine Mono Therapy
- DRUG sodium carboxymethylcellulose
- DRUG Corticosteroid Eye Drop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 2 |
What the finished NCT03418727 record still lists
NCT03418727 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 4 interventions - of which Brimonidine is the first listed.
NCT03418727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03418727 about?
NCT03418727 is a clinical study titled "Dry Eye Disease Study With Brimonidine". To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
What is the current status of trial NCT03418727?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-09-06. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT03418727?
The interventions under investigation include: Brimonidine (DRUG), Brimonidine Mono Therapy (DRUG), sodium carboxymethylcellulose (DRUG), Corticosteroid Eye Drop (DRUG).
Who is sponsoring clinical trial NCT03418727?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03418727's enrollment target sits among peer trials
84 822nd of 2000 higher than 1,173 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI